Larotrectinib Vitrakvi
A drug approved for colorectal cancer. It appears in 2 clinical trials.
What it is
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor used in colorectal cancer patients whose tumors harbor NTRK gene fusions. This targeted therapy represents a tumor-agnostic approach, meaning it is effective across different cancer types based on the presence of specific genetic alterations rather than the tumor's location. In CRC, larotrectinib is reserved for patients with metastatic disease who have confirmed NTRK gene fusions, which occur in approximately 0.5-1% of colorectal cancers.
How it works
Larotrectinib works by selectively inhibiting the TRK family of receptor tyrosine kinases (TRKA, TRKB, and TRKC), which are encoded by the NTRK1, NTRK2, and NTRK3 genes respectively. When NTRK genes become fused with other genes, they produce aberrant TRK fusion proteins that drive uncontrolled cell growth and survival. By blocking these fusion proteins, larotrectinib disrupts critical signaling pathways that promote tumor growth and metastasis.
Molecular targets
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
1 recruitingGuides that may help
Written for patients and families, in plain language.